Printer Friendly

THERION BIOLOGICS CORPORATION COMPLETES $4.1 MILLION PRIVATE PLACEMENT

 CAMBRIDGE, Mass., Sept. 29 /PRNewswire/ -- Therion Biologics Corporation announced today that it has completed a $4.1 million private placement. New investors participating in the financing are Hambrecht & Quist, New York Life and Singapore Bio-Innovations, Ltd. Existing investors participating in the financing are VCF-Therion, L.P., S.R. One, Ltd., Euclid Partners II, L.P., Loeb Investors Co. XCVI, Northwood Ventures and Aspen Venture Partners, L.P.
 "The funds from the private placement will enable us to advance the clinical development of our initial immunotherapeutic product for cancer, as well as to continue preclinical studies in our AIDS program and other areas based on our recombinant viral vector technology," commented Dennis Panicali, Ph.D., president and CEO of Therion. "The support of our company by these quality investors represents an important endorsement of our technology, research and development progress, and product development plans."
 Panicali noted that the company recently entered Phase I/II clinical trials with the National Cancer Institute for its initial cancer product, TBC-CEA, a recombinant vaccine for the treatment of colorectal, breast and lung cancers. The live recombinant cancer vaccine is designed to stimulate an immune response against cells expressing carcinoembryonic antigen (CEA), a protein associated with such cancers.
 In March, Therion entered a license and research collaboration with Harvard Medical School for a novel AIDS vaccine based on Dr. Ronald Desrosiers' work with attenuated simian immunodeficiency virus, which is related to HIV. Another Therion AIDS vaccine, TBC-3B, is a recombinant viral vector incorporating multiple HIV antigens. The company has filed an IND to conduct Phase I clinical trials on TBC-3B as a preventative vaccine for AIDS.
 Therion Biologics Corporation is engaged in the development of vaccines and immunotherapeutic products for the prevention and treatment of cancers, AIDS and other viral diseases. Therion, founded in 1991, is headquartered in Cambridge, Mass.
 -0- 9/29/93
 /CONTACT: Dennis L. Panicali, Ph.D., president & CEO of Therion Biologics, 617-876-7779; or Lynne H. Brum of Feinstein Partners , 617-577-8110 for Therion/


CO: Therion Biologics Corporation ST: Massachusetts IN: MTC SU:

DJ -- NE003 -- 6651 09/29/93 08:29 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 29, 1993
Words:348
Previous Article:AIRTRAN TO SELL STOCK
Next Article:RHODE ISLAND STUDENT LOAN AUTHORITY 1993 A & B EXPECTED 'AAA' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters